Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement

• Status: Completed
• Trial end date: 2019-07-15
• Target enrollment: 0
• Participant gender: All

Summary

A4091064 is a multicenter, long-term observational study of subjects from tanezumab interventional studies (regardless of treatment group) who undergo a total knee, hip or shoulder replacement during participation in the study. The study is designed with a total duration of subject follow-up of 24 weeks after the total joint replacement surgery. There will be two methods of data collection utilized in this study: interview by site staff via the telephone and interactive web-response system (or paper if the subject has no access to the internet).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Collaborator: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Personally signed and dated informed consent document.

• Randomized and treated with subcutaneous investigational product in a tanezumab study and has completed the study or been withdrawn from the study.

• Actual or planned total knee, hip or shoulder replacement surgery during the tanezumab study.

• Willing and able to comply with scheduled visits and other study procedures.

Exclusion Criteria:

• None.